Tilray announced the formation of Tilray Medical USA, Inc., following the Trump Administration's moves toward reclassifying cannabis as a less dangerous drug.
“We support President Trump’s decision to reschedule cannabis as a constructive and necessary evolution of U.S. federal policy. This action aligns regulation with a vast body of scientific and medical data supporting cannabis medical use and safety, economic progress, and a healthcare-focused framework, while creating a more credible foundation for medical cannabis research, clinical development, and regulatory clarity. It also signals a future shaped by innovation, responsible oversight, and evidence-based policy. We believe this landmark decision is a significant catalyst for positive change within the health, wellness, and business communities across the U.S. and a critical, incremental step toward descheduling and comprehensive regulation," said Tilray CEO Irwin D. Simon in a statement.
The direct and indirect impacts of federal cannabis rescheduling have the potential to expand access to medical research and clinical trials, improve standardization, and support the development of evidence-based cannabis therapies, the company said.
Tilray currently offers more than 200 registered medical cannabis products across international markets for therapeutic use, has served more than 500,000 registered patients globally, and has participated in more than 15 medical cannabis studies and clinical trials in partnership with leading hospitals and physicians studying cannabis for various conditions including pediatric epilepsy, cancer-induced nausea, PTSD, pain, anxiety, essential tremors, alcohol use disorder, fibromyalgia, glioblastoma, and cannabinoids and driving performance.
The company intends to strategically expand collaborations with healthcare operators and medical professionals, ensuring all partnerships are aligned with emerging regulatory medical guidelines. As part of its plan, Tilray Medical USA aims to introduce medical-grade cannabis products in targeted therapeutic formats.
